Aprea Therapeutics' Q3 net loss narrows
Aprea Therapeutics reported a narrowed Q3 net loss of $3.0 million, down from $3.8 million the previous year. The company expects its cash position to support operations until Q4 2026. Aprea is advancing its WEE1 and ATR inhibitor programs and plans to explore combination strategies for ATRN-119. R&D expenses decreased to $1.6 million from $2.8 million year-over-year. Analysts maintain a "strong buy" rating, with a median 12-month price target of $10.50, significantly above its recent closing price of $1.32.
)
Overview
- Aprea Q3 net loss narrows to $3.0 mln from $3.8 mln in prior yr
- Company’s cash position expected to support operations into Q4 2026
- Clinical progress in WEE1 and ATR inhibitor programs noted
Outlook
- Aprea plans to explore combination strategies for ATRN-119 with radiation or checkpoint inhibitors
- Company progressing with dose escalation for APR-1051 to 150 mg once daily
- Aprea has cash runway into the fourth quarter of 2026
Result Drivers
- Research and Development (R&D) expenses were $1.6 million for the quarter ended September 30, 2025, compared to $2.8 million for the third quarter of 2024
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 EPS -$0.47
Q3 Net -$3 mln
Income
Q3 -$3.10
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy.”
- Wall Street’s median 12-month price target for Aprea Therapeutics Inc is $10.50, about 87.4% above its November 11 closing price of $1.32
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
